세계의 NPHP5 망막 변성 치료 시장 : 치료 유형별, 적응증별, 유통 채널별, 지역별
Global NPHP5 Retinal Degeneration Treatment Market, By Treatment Type, By Indication, By Distribution Channel, By Geography
상품코드
:
1707354
리서치사
:
Coherent Market Insights
발행일
:
2025년 03월
페이지 정보
:
영문
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
세계의 NPHP5 망막 변성 치료 시장은 2025년에는 1,580만 달러에 달하고, 2032년에는 1억 3,330만 달러에 이를 것으로 예측되며, 2025년부터 2032년까지의 CAGR은 35.6%를 나타낼 전망입니다.
| 보고 범위 |
보고서 세부정보 |
| 기준 연도 |
2024년 |
시장 규모(2025년) |
1,580만 달러 |
| 실적 데이터 |
2020-2024년 |
예측 기간 |
2025-2032년 |
| 예측 기간 : 2025-2032년 CAGR : |
35.60% |
가치 예측(2032년) |
1억 3,330만 달러 |
그림. 세계의 NPHP5 망막 변성 치료 시장 점유율(%), 지역별(2025년)
시니어-로켄 증후군 7로도 알려진 NPHP5 망막 변성은 진행성 시각 장애를 일으키고 완전 실명으로 이어질 수 있는 드문 유전성 섬모증입니다. 이 질병은 망막 색소 변성, 네플로제 및 기타 전신 병변을 특징으로 합니다. 최근 발병 기전에 대한 연구는 섬모 기능과 같은 잠재적 창약 표적을 발견하고 치료 개발의 새로운 길을 열고 있습니다. 임상시험을 개시하고 있습니다. 시니어 로켄(SL)은 상염색체 열성 증후군이며 낭포성 신질환이 망막이영양증(망막 색소변성 또는 레이버 선천성 흑내장)을 수반하는 네프로제 관련 질환의 변종입니다.
시장 역학 :
NPHP5 망막 변성 치료 시장은 이 쇠약성 질환에 대한 효과적인 치료에 대한 높은 암메트 메디컬 니즈에 의해 견인되고 있습니다. 시장 성장을 더욱 뒷받침하고 있습니다만, 눈에의 유전자 도입에 수반하는 기술적 과제나 희귀질환 치료제의 높은 개발 비용이 계속해서 시장 수익을 억제하고 있습니다.
본 조사의 주요 특징
- 본 보고서에서는 세계의 NPHP5 망막 변성 치료 시장을 상세하게 분석하여 2024년을 기준 연도로 한 예측기간(2025-2032년) 시장 규모 및 복합연간 성장률(CAGR)을 제공합니다.
- 또, 다양한 부문에 걸친 잠재적인 수익 기회를 밝혀, 이 시장의 매력적인 투자 제안 매트릭스에 대해서 해설했습니다.
- 또한 시장 성장 촉진요인, 성장 억제요인, 기회, 신제품의 출시나 승인, 시장 동향, 지역별 전망, 주요 기업이 채용하는 경쟁 전략 등에 관한 중요한 인사이트도 제공합니다.
- 이 보고서는 세계의 NPHP5 망막 변성 치료 시장 주요 기업을 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 실적 및 전략 등의 매개 변수를 기반으로 소개합니다. Therapeutics사, MeiraGTx사, NightstaRx사, Beacon Therapeutics사, Applied Genetic Technologies Corporation사, ViGeneron사, RetinAI Medical사 등이 있습니다.
- 이 보고서로부터의 인사이트에 의해 마케팅 담당자나 기업의 경영진은 장래의 제품 발매, 유형 업, 시장 확대, 마케팅 전술에 관해서, 정보에 근거한 의사 결정을 실시할 수 있습니다.
- 세계의 NPHP5 망막 변성 치료 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통 업체, 신규 참가자, 재무 분석가 등이 업계의 다양한 이해 관계자에 대응하고 있습니다.
- 이해관계자는 세계의 NPHP5 망막변성 치료 시장 분석에 사용되는 다양한 전략 매트릭스를 통해, 의사 결정이 용이해집니다.
목차
제1장 조사의 목적과 전제조건
제2장 시장 전망
- 보고서 설명
- 주요 요약
- 일관된 기회 맵(COM)
제3장 시장 역학, 규제, 동향 분석
- 시장 역학
- 계발 캠페인의 전개 증가
- 긴 승인 기간
- 아시아태평양 및 라틴아메리카의 신흥 시장
- 주요 하이라이트
- 규제 시나리오
- 시장 동향
- PEST 분석
- PORTER 분석
- 제품 발매
- 역학
- 합병, 인수 및 제휴
제4장 세계의 NPHP5 망막 변성 치료 시장 - 코로나바이러스(COVID-19) 팬데믹의 영향
- COVID-19 역학
- 공급측과 수요측의 분석
- 경제에 미치는 영향
제5장 세계의 NPHP5 망막 변성 치료 시장, 치료 유형별(2020-2032년)
제6장 세계의 NPHP5 망막 변성 치료 시장, 적응증별(2020-2032년)
- 망막 색소 침착증
- 레베르 선천성 무모증
- 어셔 증후군
- 기타
제7장 세계의 NPHP5 망막 변성 치료 시장, 유통 채널별(2020-2032년)
제8장 세계의 NPHP5 망막 변성 치료 시장, 지역별(2020-2032년)
- 북미
- 유럽
- 아시아태평양
- 라틴아메리카
- 중동
- 아프리카
제9장 경쟁 구도
- 기업 프로파일
- ProQR Therapeutics
- Editas Medicine
- Nanoscope Therapeutics, Inc.
- jCyte, Inc.
- Biogen
- Novartis AG
- Spark Therapeutics
- MeiraGTx
- NightstaRx
- Beacon Therapeutics
- Applied Genetic Technologies Corporation
- ViGeneron
- RetinAI Medical
제10장 섹션
KTH
영문 목차
Global NPHP5 Retinal Degeneration Treatment Market is estimated to be valued at USD 15.8 Mn in 2025 and is expected to reach USD 133.3 Mn by 2032, growing at a compound annual growth rate (CAGR) of 35.6% from 2025 to 2032.
| Report Coverage |
Report Details |
| Base Year: |
2024 |
Market Size in 2025: |
USD 15.8 Mn |
| Historical Data for: |
2020 To 2024 |
Forecast Period: |
2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: |
35.60% |
2032 Value Projection: |
USD 133.3 Mn |
Figure. Global NPHP5 Retinal Degeneration Treatment Market Share (%), By Region 2025
NPHP5 retinal degeneration, also known as Senior-Loken syndrome 7, is a rare genetic ciliopathy that causes progressive visual impairment and can lead to complete blindness. It is caused by mutations in the NPHP5 gene, which encodes for nephrocystin-5, a protein critical for cilia function. The condition is characterized by retinitis pigmentosa, nephronophthisis, and other systemic involvement. Currently, there is no approved treatment for NPHP5 retinal degeneration, and management involves low vision aids and supportive care. However, recent research investigating the pathogenic mechanisms has uncovered potential drug targets such as cilia function, which is opening up new avenues for treatment development. Several biopharmaceutical companies have started clinical trials evaluating gene therapy and other novel therapeutic approaches to restore vision in these patients. Senior-Loken (S-L) is an autosomal recessive syndrome and a variant of the nephronophthisis-associated disorders, in which the cystic kidney disease is associated with retinal dystrophy (retinitis pigmentosa or Leber congenital amaurosis). It is a deleterious disease that culminates in blindness and renal failure.
Market Dynamics:
The NPHP5 retinal degeneration treatment market is driven by the high unmet medical need for an effective treatment for this debilitating condition. As per estimates, NPHP5 retinal degeneration has a prevalence of 1 in 200,000 live births globally. The increasing research focus on cilia pathways and recent breakthroughs in retinal gene therapy are further boosting market growth by expanding therapeutic opportunities. However, technical challenges associated with ocular gene delivery and the high costs of developing orphan disease therapies continue to restrain market revenues. On the other hand, partnerships between biotech firms and research institutions, growing public-private funding for rare disease, research and development present lucrative opportunities for market players.
Key features of the study:
- This report provides in-depth analysis of the global NPHP5 retinal degeneration treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2025-2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global NPHP5 retinal degeneration treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies - Key companies covered as a part of this study include ProQR Therapeutics, Editas Medicine, Nanoscope Therapeutics, Inc., jCyte, Inc., Biogen, Novartis AG, Spark Therapeutics, MeiraGTx, NightstaRx, Beacon Therapeutics, Applied Genetic Technologies Corporation, ViGeneron and RetinAI Medical
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global NPHP5 retinal degeneration treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global NPHP5 retinal degeneration treatment market
Detailed Segmentation:
- Global NPHP5 Retinal Degeneration Treatment Market, By Treatment Type
- Gene Therapy
- Cell Therapy
- Drug Therapy
- Others
- Global NPHP5 Retinal Degeneration Treatment Market, By Indication
- Retinitis Pigmentosa
- Leber Congenital Amaurosis
- Usher Syndrome
- Others
- Global NPHP5 Retinal Degeneration Treatment Market, By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
- Global NPHP5 Retinal Degeneration Treatment Market, By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Company Profiles
- ProQR Therapeutics
- Editas Medicine
- Nanoscope Therapeutics, Inc.
- jCyte, Inc.
- Biogen
- Novartis AG
- Spark Therapeutics
- MeiraGTx
- NightstaRx
- Beacon Therapeutics
- Applied Genetic Technologies Corporation
- ViGeneron
- RetinAI Medical
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Treatment Type
- Market Snippet, By Indication
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Increasing Launch of Awareness Campaigns
- Long approval timelines
- Emerging markets in Asia Pacific and Latin America
- Key Highlights
- Regulatory Scenario
- Market Trends
- PEST Analysis
- PORTER's Analysis
- Product Launches
- Epidemiology
- Mergers, Acquisitions, and Collaborations
4. Global NPHP5 Retinal Degeneration Treatment Market - Impact of Coronavirus (COVID-19) Pandemic
- COVID-19 Epidemiology
- Supply Side and Demand Side Analysis
- Economic Impact
5. Global NPHP5 Retinal Degeneration Treatment Market, By Treatment Type, 2020-2032, (US$ Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Gene Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
- Drug Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
6. Global NPHP5 Retinal Degeneration Treatment Market, By Indication, 2020-2032, (US$ Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Retinitis Pigmentosa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
- Leber Congenital Amaurosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
- Usher Syndrome
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
7. Global NPHP5 Retinal Degeneration Treatment Market, By Distribution Channel, 2020-2032, (US$ Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
8. Global NPHP5 Retinal Degeneration Treatment Market, By Region, 2020-2032, (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Region, 2021 -2032
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032,(US$ Mn)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Company Profile
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Nanoscope Therapeutics, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Applied Genetic Technologies Corporation
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Analyst Views
10. Section
- References
- Research Methodology
- About us
관련자료
